Engineered antibodies with increased activity to recruit complement

Journal of Immunology

Volumn 166, Issue 4, 2001, Pages 2571-2575

  Idusogie, E E ^a   Pin Yee Wong, ^a   Presta, L G ^a   Gazzano Santoro, H ^a   Totpal, K ^a   Ultsch, M ^a   Mulkerrin, M G ^a  

^a Abgenix ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENT COMPONENT C1Q; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; RITUXIMAB;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; GENE MUTATION; HUMAN; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING;

EID: 0035865063     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.4.2571     Document Type: Article

References (25)

1. Reaction between the isolated subunits of the complement component C1q and IgG-complexes
2. Immunoglobulin G: Functional sites
3. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc
4. The binding site for C1q on IgG
5. Biology of human immunoglobulin G Fc receptors
6. Fc receptors: Rubor redux
7. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
8. Targeted anti-cancer therapy using Rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
9. Construction and characterization of an active factor VIII variant lacking the central one third of the molecule
10. Rapid and efficient site-specific mutagenesis without phenotypic selection
11. Transient production of proteins using an adenovirus transformed cell line
12. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody
13. H2 influence the relative abilities of IgG2 and IgG3 to activate complement
14. Additivity of mutational effects in proteins
15. IgG-Fc-mediated effector functions: Molecular definition of interaction sites for effector ligands and the role of glycosylation
16. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis
17. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharide
18. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from staphylococcus aureus at 2.9- and 2.8-A resolution
19. Human antibody effector function
20. Autoantibodies against C1q: View on clinical relevance and pathogenic role
21. Immunoglubulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation
22. Role of Fc fragments in inhibition of xenogenic hyperacute rejection by intravenous immunoglobulin
23. The effector functions of immunoglobulins: Implications for therapy